# Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).

> **NCT05365841** · — · UNKNOWN · sponsor: **University of Crete** · enrollment: 85 (estimated)

## Conditions studied

- Severe Eosinophilic Asthma w/wo CRSwNP

## Interventions

- **DRUG:** Mepolizumab 100 MG

## Key facts

- **NCT ID:** NCT05365841
- **Lead sponsor:** University of Crete
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-15
- **Primary completion:** 2025-05-15
- **Final completion:** 2025-11-16
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2024-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05365841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05365841, "Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05365841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*